ArticleThe American journal of case reports2026
Delayed Diagnosis of Type 1 Gaucher Disease at Age 15 After Years of Mild Cytopenias and Splenomegaly: A Case Report and Long-Term Follow-Up.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Gaucher disease (GD) is the most common lysosomal storage disorder caused by glucocerebrosidase deficiency. Type 1 GD (GD1) often presents with nonspecific manifestations, including splenomegaly, cytopenias, growth impairment, and skeletal involvement, leading to delayed diagnosis and irreversible complications. This report highlights the delayed diagnosis of GD1 in a patient with longstanding mild manifestations and emphasizes the importance of considering GD in patients with unexplained cytopenias and splenomegaly. CASE REPORT We describe a male patient with GD1 whose first manifestations appeared in infancy and included splenomegaly. During childhood, persistent cytopenias, hepatosplenomegaly, and growth deceleration were observed; however, the diagnosis remained unrecognized. At age 14, the patient developed severe skeletal pain accompanied by fever, prompting further diagnostic evaluation. Imaging studies revealed bone marrow abnormalities, and bone biopsy demonstrated foamy macrophages but did not establish a definitive diagnosis. At age 15, GD1 was suspected and subsequently confirmed by enzymatic testing, biomarker assessment, and genetic analysis. Enzyme replacement therapy with imiglucerase resulted in clinical improvement, reduced organomegaly, and stabilization of laboratory parameters. The patient subsequently underwent a structured transition from pediatric to adult care without treatment interruption. CONCLUSIONS GD should be considered in patients with unexplained splenomegaly and persistent cytopenias, even when early manifestations are mild and nonspecific. Early recognition and disease-specific diagnostic testing may reduce diagnostic delay, facilitate timely treatment initiation, and help prevent irreversible complications. This case also highlights the importance of a structured transition from pediatric to adult care in maintaining long-term treatment continuity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.